NFL BIOSCIENCES: INCREASE IN CAPITAL OF GB HOLDING BY EXERCISE OF BSA FOR €0.5 M AND COMMITMENT TO CONSERVE SHARES
NFL BIOSCIENCES (Euronext Growth Paris – FR0014003XT0 – ALNFL), a biopharmaceutical company that develops botanical drugs for the treatment of dependencies and addictions, was informede of the exercise of 100,000 Goods share subscription (“BSA « ) held by GB Holding, holding company of Mr Gerard Leduc, giving rise to the creation of 1,000,000 new shares. GB Holding held as of June 29, 2023, 850,000 shares representing 11.17% of the capital of NFL Biosciences and got involved to conserve all shares held to date for a period of 9 months minimum.
Gérard Leduc is a recognized entrepreneur in the pharmaceutical sector, he notably founded, managed and sold Ethypharm, a European pharmaceutical laboratory specializing in pathologies of the Central Nervous System (CNS) and Hospital Injectables which had more than 800 employees. Since July 2018, GB Holding has held 100,000 BSA exercisable until July 2, 2023 at a price of €0.50 per share, one warrant giving the right to subscribe to 10 shares with a par value of €0.03. Their exercise represents a cash contribution of €0.5 million for the Company and gives rise to the issue of 1,000,000 new shares. GB Holding has entered into a lock-up commitment, with Invest Securities, relating to 850,000 shares subscribed within the framework of the exercise of the BSA, for 9 months following the date of settlement-delivery of the new shares, i.e. until 31 March 2024. The new shares were issued today by the Company and immediately assimilated to the existing shares (ISIN code FR0014003XT0).
On the occasion of the exercise of his BSA, Mr. Leduc adeclear “I am delighted to continue to contribute to the hit of NFL Biosciences. Addiction products have always been of great interest to me. The NFL-101, for smoking cessation, is a product potentially revolutionary with a brand new mechanism of action. He could change the waynot of which this addiction is treatede so far « .
Ignacio Faus, Chairman and CEO of NFL Biosciences says » Of the her backgrounddateionMr. Leduc had chosen to support NFL Biosciences by participating in the first one fundraising of the society. Today, we think that shas decision exercise of BSA and retention of‘actions NFL Biosciences East proof of its confidence in the potential of our drug candidates and in particular of NFL-101 for smoking cessation, the first results of the two clinical studies of which are expected inx 3th and 4th quarters 2023. »
Following the exercise of the warrants held by GB Holding, the capital of NFL Biosciences increased to 7,606,769 shares, compared to 6,606,769 before exercise.
The detailed characteristics of the capital and potential capital before this BSA exercise are indicated in particular in the 2022 Annual Financial Report made available on April 28, 2023 and available on the Company’s website, « Documentation » page: https://www. .nflbiosciences.com
AT About NFL Biosciences
NFL Biosciences is a biopharmaceutical company based in the Montpellier region that develops botanical drug candidates for the treatment of addictions. NFL Biosciences aims to bring new therapeutic, natural, safer and more effective solutions to the entire world population, without forgetting countries with low or middle income levels. Its most advanced product, called NFL-101, is a standardized, nicotine-free tobacco leaf extract protected by three patent families. NFL Biosciences intends to offer smokers who wish to quit a natural, safe, simplified and personalized administration alternative. NFL Biosciences is also developing NFL-301, a natural drug candidate for the reduction of alcohol consumption and has a drug development project for the treatment of cannabis use disorders.
NFL Biosciences shares are listed on Euronext Growth Paris (FR0014003XT0 – ALNFL). The company is qualified as an “Innovative Company” eligible for FCPI investment. More information on www.nflbiosciences.com
Bruno Lafont – firstname.lastname@example.org – 04 11 93 76 67 Calyptus Agency – email@example.com – 01 53 65 68 68